The great escape; the hallmarks of resistance to antiangiogenic therapy.
about
Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune DysfunctionTetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapyEpidermal growth factor, latrophilin, and seven transmembrane domain-containing protein 1 marker, a novel angiogenesis markerCompensatory angiogenesis and tumor refractorinessEscaping Antiangiogenic Therapy: Strategies Employed by Cancer CellsHMGA2 promotes vasculogenic mimicry and tumor aggressiveness by upregulating Twist1 in gastric carcinomaRapid optimization of drug combinations for the optimal angiostatic treatment of cancerA streamlined search technology for identification of synergistic drug combinations.Novel Small Molecule JP-153 Targets the Src-FAK-Paxillin Signaling Complex to Inhibit VEGF-Induced Retinal Angiogenesis.Original insights on thrombospondin-1-related antireceptor strategies in cancer.CD44 enhances tumor aggressiveness by promoting tumor cell plasticity.Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.Antiangiogenic cancer treatment: The great discovery and greater complexity (Review).The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies.Insulin-like growth factor axis targeting in cancer and tumour angiogenesis - the missing link.Modulation of VEGF receptor 2 signaling by protein phosphatases.Tumor vascular infarction: prospects and challenges.The therapeutic potential of targeting ABC transporters to combat multi-drug resistance.Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.miRNAs: micro-managers of anticancer combination therapies.Epithelial-to-Pericyte Transition in Cancer.Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B.HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells.Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.A genomic screen for angiosuppressor genes in the tumor endothelium identifies a multifaceted angiostatic role for bromodomain containing 7 (BRD7).Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.Paragangliomas arise through an autonomous vasculo-angio-neurogenic program inhibited by imatinib.Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression.Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.Targeting the tumour stroma to improve cancer therapy.Contribution of tumor endothelial cells to drug resistance: anti-angiogenic tyrosine kinase inhibitors act as p-glycoprotein antagonists.DNA Methylation Signatures Predicting Bevacizumab Efficacy in Metastatic Breast Cancer.Autophagy Inhibition Promotes Bevacizumab-induced Apoptosis and Proliferation Inhibition in Colorectal Cancer CellsRepurposing antimalarial aminoquinolines and related compounds for treatment of retinal neovascularization
P2860
Q26749333-C8AD1610-6F95-4147-9C6C-48FBD732D0BEQ26749391-9EE6D6F9-DFA3-44E9-9BF0-5FACDCDD77DFQ26771513-A7CCBC47-3B35-474F-886B-54773EE1C4FBQ26851916-BE888009-C59A-410F-8D25-B7A2447B8661Q28067753-EAC42BBD-BCD7-4228-9D44-FED290105098Q33714914-1F001936-994F-4890-AE69-A8DF712093D1Q35757208-022ACA86-8F23-4A35-968A-F3A456790E77Q36101810-BA574F9C-22C5-4FDE-AEF0-F8376C112050Q36212445-BFCDF1D7-EB11-455D-B18F-FEBB6D566B62Q36221374-C125D5D9-DB72-411F-9E51-D4637DE0BD7AQ36260608-30F0FE5A-8B82-4463-BC3D-B14217B08D4EQ36932216-1A99CF3E-86A0-4C13-9248-72DECD7032D9Q37337814-6E9261A6-94D2-48E6-87D0-F297361E32B0Q38675589-8D656B85-2261-40D9-85CE-4D5C149E2421Q38990201-0CAD2841-49F8-4AA7-90AF-9561602D3E4CQ39020269-C05BDE99-CE7E-47BE-B4F5-18AA23EE81EDQ39065317-B307CF45-DF36-4451-972B-F1635A446B5EQ39196784-A4B4EFBB-5C94-4841-97BB-D68EB58080D2Q39210287-4EFA7216-BAFB-4549-A639-8C839B0B9F3BQ39220891-9D26C7F6-547C-4DE4-903D-3568B5B985DCQ39285150-32A6EC4E-98AE-43D9-B4D7-95D9E07FED68Q39414887-A3981783-2199-4FC8-8846-B24E7D1A76BAQ41437410-01DAD170-BFA1-407D-A902-05364F5DAD3CQ41472694-D6FE2DB4-696F-4152-898E-79A3E9CE88A1Q41679466-747C8B26-CD25-4EF1-8C1F-F1F448D20A70Q41892380-4ABDCD65-3D2A-40A6-939D-0A4F25D63382Q46493497-3134EFD2-C8A7-46A5-A074-9B20263AE51CQ47218543-014C3ED4-389D-4159-90DB-9AADA5EB31F3Q47228308-C7587E0A-BFEC-4F39-9E29-D354D7CADFE9Q47668446-B6739372-419F-49D7-A255-F6B28E136111Q48184079-DD7F972D-B005-4B30-859A-D32FAA4FC971Q49887919-C8AED31F-0AA0-4922-A4A0-3DCB827062FFQ52322982-11C1CDBF-C014-445B-A698-13F4FE603115Q52882763-10A005CF-5277-47DD-8C27-202AD33649DFQ55332979-7E8DE12A-018E-4063-87AF-EC41EF07756EQ57116293-7A8A4DB4-E791-4C0C-9077-B620B07FC6A7Q58747914-F303DEA8-8D92-4F71-924C-9F6F3334B6C7
P2860
The great escape; the hallmarks of resistance to antiangiogenic therapy.
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The great escape; the hallmarks of resistance to antiangiogenic therapy.
@ast
The great escape; the hallmarks of resistance to antiangiogenic therapy.
@en
The great escape; the hallmarks of resistance to antiangiogenic therapy.
@nl
type
label
The great escape; the hallmarks of resistance to antiangiogenic therapy.
@ast
The great escape; the hallmarks of resistance to antiangiogenic therapy.
@en
The great escape; the hallmarks of resistance to antiangiogenic therapy.
@nl
prefLabel
The great escape; the hallmarks of resistance to antiangiogenic therapy.
@ast
The great escape; the hallmarks of resistance to antiangiogenic therapy.
@en
The great escape; the hallmarks of resistance to antiangiogenic therapy.
@nl
P2093
P3181
P356
P1476
The great escape; the hallmarks of resistance to antiangiogenic therapy
@en
P2093
Arjan W Griffioen
Elisabeth J M Huijbers
Judy R van Beijnum
Patrycja Nowak-Sliwinska
P304
P3181
P356
10.1124/PR.114.010215
P577
2015-01-01T00:00:00Z